November 30, 2022Open Access

Lecanemab in Early Alzheimer’s Disease

Key Points

Key points are not available for this paper at this time.

Abstract

Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer's disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Dyck et al. (Wed,) studied this question.

synapsesocial.com/papers/69d72f245dca7d66cbbef2f3 https://doi.org/https://doi.org/10.1056/nejmoa2212948

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice2014 · 271 citations
2CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”2016 · 64 citations
3Determining clinically meaningful decline in preclinical Alzheimer disease2019 · 136 citations
4Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease2011 · 360 citations
5The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation2001 · 1,206 citations

Bookmark

View Full Paper